HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Francisco J Esteva Selected Research

MicroRNAs (MicroRNA)

2/2018Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process.
6/2015CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
5/2012Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Francisco J Esteva Research Topics

Disease

138Breast Neoplasms (Breast Cancer)
04/2024 - 04/2002
79Neoplasms (Cancer)
02/2024 - 06/2002
8Disease Progression
12/2018 - 04/2002
8Neoplasm Metastasis (Metastasis)
01/2018 - 07/2002
6Cardiotoxicity
10/2021 - 09/2006
5Neutropenia
01/2021 - 01/2017
4Triple Negative Breast Neoplasms
10/2018 - 03/2010
4Carcinoma (Carcinomatosis)
03/2015 - 01/2007
4Carcinogenesis
10/2014 - 12/2008
4Pathologic Complete Response
04/2014 - 08/2005
3Thrombocytopenia (Thrombopenia)
10/2020 - 07/2002
3Brain Neoplasms (Brain Tumor)
01/2018 - 07/2014
3Noninfiltrating Intraductal Carcinoma (DCIS)
02/2014 - 01/2007
3Residual Neoplasm
12/2009 - 08/2004
2Pain (Aches)
12/2020 - 06/2018
2Fatigue
12/2020 - 01/2019
2Stomach Neoplasms (Stomach Cancer)
10/2019 - 08/2018
2Insulin Resistance
01/2019 - 01/2013
2Hyperinsulinism (Hyperinsulinemia)
01/2019 - 07/2014
2Overweight
01/2019 - 01/2013
2Febrile Neutropenia
01/2019 - 01/2017
2Heart Failure
10/2018 - 07/2014
2Ductal Carcinoma
04/2016 - 10/2014
2Lymphatic Metastasis
06/2012 - 05/2012
2Inflammatory Breast Neoplasms
11/2009 - 10/2006
2Ovarian Neoplasms (Ovarian Cancer)
12/2008 - 09/2005

Drug/Important Bio-Agent (IBA)

63Trastuzumab (Herceptin)FDA Link
10/2020 - 04/2002
20Proteins (Proteins, Gene)FDA Link
12/2018 - 08/2002
19ErbB Receptors (EGF Receptor)IBA
03/2024 - 01/2004
17human ERBB2 proteinIBA
04/2024 - 01/2003
16Hormones (Hormone)IBA
01/2021 - 10/2003
15Monoclonal AntibodiesIBA
01/2023 - 06/2003
14AnthracyclinesIBA
10/2021 - 04/2002
11Doxorubicin (Adriamycin)FDA LinkGeneric
05/2009 - 06/2002
10Biomarkers (Surrogate Marker)IBA
02/2018 - 06/2002
10Lapatinib (GW572016)FDA Link
10/2015 - 11/2005
9Estrogen ReceptorsIBA
10/2018 - 07/2004
7Estrogens (Estrogen)FDA Link
01/2019 - 07/2003
7Taxoids (Taxanes)IBA
08/2017 - 09/2003
7Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2009 - 06/2002
6taxaneIBA
10/2020 - 09/2003
6Tyrosine Kinase InhibitorsIBA
03/2015 - 06/2003
6Docetaxel (Taxotere)FDA Link
04/2014 - 04/2002
6Fluorouracil (Carac)FDA LinkGeneric
01/2007 - 06/2002
5ribociclibIBA
12/2020 - 01/2018
5EverolimusFDA Link
01/2019 - 10/2007
5Progesterone Receptors (Progesterone Receptor)IBA
10/2018 - 10/2003
5Paclitaxel (Taxol)FDA LinkGeneric
08/2017 - 05/2004
4Immunoconjugates (Immunoconjugate)IBA
02/2024 - 01/2009
4Biosimilar PharmaceuticalsIBA
10/2019 - 01/2017
4pertuzumabIBA
08/2017 - 04/2004
4Epidermal Growth Factor (EGF)IBA
08/2017 - 12/2008
4Phosphotransferases (Kinase)IBA
03/2015 - 01/2003
4Growth Factor ReceptorsIBA
02/2010 - 01/2003
4Antisense OligonucleotidesIBA
12/2008 - 10/2003
3Ado-Trastuzumab EmtansineIBA
02/2024 - 10/2015
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
02/2024 - 01/2004
3Fulvestrant (Faslodex)FDA Link
12/2020 - 01/2018
3Letrozole (Femara)FDA LinkGeneric
01/2019 - 06/2018
3Metformin (Glucophage)FDA LinkGeneric
01/2019 - 01/2013
3Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2019 - 07/2004
3MicroRNAs (MicroRNA)IBA
02/2018 - 05/2012
3Messenger RNA (mRNA)IBA
02/2014 - 01/2007
3TamoxifenFDA LinkGeneric
02/2012 - 05/2005
3IGF Type 1 Receptor (IGF 1 Receptor)IBA
02/2010 - 12/2005
3Tumor Biomarkers (Tumor Markers)IBA
12/2008 - 10/2002
3ParaffinIBA
05/2005 - 11/2003
2Linoleic Acid (Linoleate)IBA
12/2020 - 08/2019
2CT-P6IBA
10/2019 - 01/2017
2TOR Serine-Threonine KinasesIBA
01/2019 - 10/2005
2exemestane (Aromasin)FDA Link
01/2019 - 01/2013
2Cytotoxins (Cytolysins)IBA
10/2018 - 01/2015
2RNA (Ribonucleic Acid)IBA
02/2018 - 01/2017
2AntibodiesIBA
02/2014 - 04/2004
2Transcription Factors (Transcription Factor)IBA
11/2012 - 12/2005
2Carboplatin (JM8)FDA LinkGeneric
07/2012 - 06/2002
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
05/2012 - 05/2005
2Erlotinib Hydrochloride (CP 358,774)FDA Link
02/2012 - 11/2009
2Antineoplastic Agents (Antineoplastics)IBA
12/2010 - 06/2006
2TensinsIBA
10/2010 - 01/2009
2DNA (Deoxyribonucleic Acid)IBA
03/2010 - 08/2008
2Capecitabine (Xeloda)FDA Link
02/2010 - 09/2003
2Neuregulin-1 (Neuregulin 1)IBA
01/2010 - 08/2002
2Plasminogen Activators (Plasminogen Activator)IBA
12/2008 - 01/2004
2Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
12/2008 - 01/2004
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
12/2008 - 05/2006
2PlatinumIBA
01/2007 - 06/2002
2Formaldehyde (Formol)FDA Link
05/2005 - 07/2004
1trastuzumab deruxtecanIBA
02/2024
1IntegrinsIBA
01/2021

Therapy/Procedure

69Therapeutics
04/2024 - 04/2002
34Drug Therapy (Chemotherapy)
01/2019 - 04/2002
17Neoadjuvant Therapy
03/2024 - 06/2002
5Adjuvant Chemotherapy
12/2019 - 02/2004
3Mastectomy (Mammectomy)
04/2024 - 05/2007
3Biological Therapy
01/2019 - 01/2003
2Immunotherapy
01/2019 - 01/2017
2Combination Drug Therapy (Combination Chemotherapy)
04/2010 - 02/2006
2Radiotherapy
04/2009 - 01/2007
1Drug Tapering
01/2021